# OnCo record platinum-sensitivity (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/platinum-sensitivity/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "platinum-sensitivity" ;
  schema:name "Platinum-sensitive / platinum-resistant"@en ;
  schema:alternateName "platinum-sensitive"@en, "platinum sensitive"@en, "platinum-resistant"@en, "platinum resistant"@en, "platinum-refractory"@en, "platinum-free interval"@en, "PFI"@en, "platinum-eligible"@en, "platinum-ineligible"@en, "platinum-pretreated"@en, "post-platinum"@en, "platinum doublet"@en, "platinum-based"@en, "platinum-based chemotherapy"@en, "platinum doublets"@en, "platinum-etoposide"@en, "carboplatin-paclitaxel"@en, "platinum resistance"@en ;
  schema:description "Whether a cancer that responded to platinum chemotherapy came back more than six months later (sensitive, so platinum can be used again) or sooner (resistant, so something else is needed). The dividing line shapes ovarian and small-cell lung cancer treatment."@en ;
  schema:url <https://onco.cc/terms/platinum-sensitivity/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Platinum-based_antineoplastic> ;
  schema:citation <https://en.wikipedia.org/wiki/Platinum-based_antineoplastic> ;
  onco:related <https://onco.cc/terms/relapsed-refractory/>, <https://onco.cc/terms/rechallenge/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/doublet-triplet/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> .